首页 | 本学科首页   官方微博 | 高级检索  
     


Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
Authors:A. C. Ludolph  J. Kassubek  B. G. Landwehrmeyer  E. Mandelkow  E.‐M. Mandelkow  D. J. Burn  D. Caparros‐Lefebvre  K. A. Frey  J. G. De Yebenes  T. Gasser  P. Heutink  G. Höglinger  Z. Jamrozik  K. A. Jellinger  A. Kazantsev  H. Kretzschmar  A. E. Lang  I. Litvan  J. J. Lucas  P. L. McGeer  S. Melquist  W. Oertel  M. Otto  D. Paviour  T. Reum  A. Saint‐Raymond  J. C. Steele  M. Tolnay  H. Tumani  J. C. Van Swieten  M. T. Vanier  J.‐P. Vonsattel  S. Wagner  Z. K. Wszolek
Affiliation:1. Department of Neurology, University of Ulm, Ulm, Germany;2. These authors contributed equally to the work.;3. Max Planck Unit for Structural Molecular Biology, c/o DESY, Notkestr, Hamburg, Germany;4. Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK;5. Centre Hospitalier de Valenciennes, Résidence du Val d’Escaut, Avenue Desandrouin, Valenciennes, France;6. University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI, USA;7. Hospital Ramon y Cajal, Neurology, Carretera Colmenar, Madrid, Spain;8. Universit?tsklinikum Tübingen, Zentrum für Neurologie, Hoppe‐Seyler‐Strasse, Tübingen, Germany;9. VU University Medical Center, Department of Clinical Genetics and Anthropogenet, van der Boechorststraat, Amsterdam, the Netherlands;10. Philipps‐Universit?t, Neurologie, Rudolf‐Bultmann‐Strasse, Marburg, Germany;11. Medical University of Warsaw, Neurology, Banacha, Warsaw, Poland;12. Institute of Clinical Neurobiology, Kenyongasse, Vienna, Austria;13. Massachusetts General Hospital, MIND/Harvard Medical School, Charlestown, MA, USA;14. Institut für Neuropathologie, BrainNet (German Brain Bank), Feodor‐Lynen‐Strasse, Munich, Germany;15. Toronto Western Hospital, Movement Disorders Center, Toronto, ON, Canada;16. University of Louisville, School of Medicine/Department of Neurology, Louisville, KY, USA;17. Centro de Biologica Molecular “Severo Ochoa,” Universidad Autonoma de Madrid and CiberNed, Cantoblanco, Madrid, Spain;18. University of British Columbia, Kinsmen Laboratory of Neurological Research, Vancouver, BC, Canada;19. Mayo Clinic, Department of Neuroscience, Jacksonville, FL, USA;20. National Hospital for Neurology, Dementia Research Centre, London, England;21. Bundesinstitut für Arzneimittel & Medizinprodukte, Wissenschaftlicher Service/Klinische Prüfungen, Georg‐Kiesinger‐Allee, Bonn, Germany;22. European Medicines Agency (EMEA), Scientific Advice and Orphan Drugs Sector, 7 Westferry Circus, Canary Wharf, London, England;23. Guam Memorial Hospital, Neurology, Carlos Camacho Way, Tamuning, Guam;24. Institut für Pathologie, Sch?nbeinstrasse, Basel, Switzerland;25. University Hospital Rotterdam, Department of Neurology, Erasmus MC, Dr Molewaterplein, GD Rotterdam, the Netherlands;26. Institut National de la Santé et de la Recherche Médicale, Unit 820, La?nnec Medical School, Lyon, France;27. New York Brain Bank, Columbia University, Pathology, Babies Hospital, New York, NY, USA;28. Deutsche PSP‐Gesellschaft e.V. (PSP Germany), c/o S. Wagner, K?nneritzstrasse, Leipzig, Germany;29. Mayo Clinic, Department of Neurology, Jacksonville, FL, USA
Abstract:Tauopathies with parkinsonism represent a spectrum of disease entities unified by the pathologic accumulation of hyperphosphorylated tau protein fragments within the central nervous system. These pathologic characteristics suggest shared pathogenetic pathways and possible molecular targets for disease-modifying therapeutic interventions. Natural history studies, for instance, in progressive supranuclear palsy, frontotemporal dementia with parkinsonism linked to chromosome 17, corticobasal degeneration, and Niemann-Pick disease type C as well as in amyotrophic lateral sclerosis/Parkinson–dementia complex permit clinical characterization of the disease phenotypes and are crucial to the development and validation of biological markers for differential diagnostics and disease monitoring, for example, by use of neuroimaging or proteomic approaches. The wide pathologic and clinical spectrum of the tauopathies with parkinsonism is reviewed in this article, and perspectives on future advances in the understanding of the pathogenesis are given, together with potential therapeutic strategies.
Keywords:corticobasal degeneration    frontotemporal dementia with parkinsonism linked to chromosome 17    microtubule-associated protein tau    multiple system atrophy    Parkinson disease    parkinsonism    progressive supranuclear palsy    tauopathies
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号